Get started
Author

Jennifer Desrosiers

Observed name: J. Desrosiers
OpenAlex ID: A5108939899
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
2024 · A.C. Garrido-Castro, S.E. Kim, et al. · Annals of Oncology · 37
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
2025 · Ana C Garrido-Castro, Noah Graham, et al. · Journal for ImmunoTherapy of Cancer · 20
PDF
Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+/HER2- Cohort
2025 · Erica Mayer, Noah Graham, et al. · Clinical Cancer Research · 7
Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts
2026 · E. L. Mayer, N. Graham, et al. · Clinical Cancer Research · 4
Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer.
2025 · Ana Christina Garrido-Castro, Aparna Gorthi, et al. · Journal of Clinical Oncology · 1
PDF
ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.
2026 · Payal Deepak Shah, Angela DeMichele, et al. · Journal of Clinical Oncology
424RO SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC)
2026 · A.C. Garrido-Castro, T. Li, et al. · ESMO Open
Abstract P2-09-24: Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial
2025 · Ana Garrido-Castro, Se Eun Kim, et al. · Clinical Cancer Research
Works count: 8
Citation count: 68
H-index: 4
I10-index: 2
Year
Topic
Type